Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763738 | 0.91 | ALDH1A1 (0.43) | NR4A2KLK7KLK14KLK5ALDH1A1 | |
| SCHEMBL13201932 | 0.87 | KDM4E (0.47) | KDM4EALDH1A1POLBNQO2MAPT | |
| SCHEMBL13757342 | 0.86 | KDM4E (0.50) | CRHR1KDM4ENR4A2ALDH1A1NQO2 | |
| SCHEMBL13757461 | 0.86 | NR4A2 (0.38) | KDM4ENR4A2ALDH1A1POLBLMNA | |
| SCHEMBL13763686 | 0.86 | ALDH1A1 (0.44) | CRHR1KDM4ENR4A2ALDH1A1POLB | |
| SCHEMBL13385166 | 0.85 | NR4A2 (0.42) | NR4A2ALDH1A1POLBKMT2AMAPT | |
| SCHEMBL8142999 | 0.84 | MAPT (0.49) | CRHR1KDM4EALDH1A1POLBNQO2 | |
| SCHEMBL13763664 | 0.84 | HPGD (0.40) | CRHR1KDM4ENR4A2ALDH1A1POLB | |
| SCHEMBL13763607 | 0.84 | ALDH1A1 (0.42) | KDM4ENR4A2KLK7KLK14KLK5 | |
| SCHEMBL13763563 | 0.83 | PDE10A (0.43) | KDM4EALDH1A1POLBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2006007700-A1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | CRHR1 1607/4885KDM4E 3511/4885NR4A2 1614/4885 |
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | CRHR1 4587/4885KDM4E 2496/4885NR4A2 3771/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CRHR1 4587/4885KDM4E 2496/4885NR4A2 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.